Compare JCE & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JCE | RCKT |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.2M | 277.7M |
| IPO Year | 2007 | 2014 |
| Metric | JCE | RCKT |
|---|---|---|
| Price | $15.90 | $2.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $8.31 |
| AVG Volume (30 Days) | 27.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,494.26 |
| P/E Ratio | ★ N/A | $9.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.99 | $2.03 |
| 52 Week High | $17.45 | $5.45 |
| Indicator | JCE | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 32.29 | 35.74 |
| Support Level | $15.59 | N/A |
| Resistance Level | $16.01 | $2.73 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 0.00 | 13.49 |
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.